Therapeutic benefits of cilazapril in patients with syndrome X

Basit Öğe Kaydı
dc.contributor.authorNalbantgil, I
dc.contributor.authorOnder, R
dc.contributor.authorAltintig, A
dc.contributor.authorNalbantgil, S
dc.contributor.authorKiliccioglu, B
dc.contributor.authorBoydak, B
dc.contributor.authorYilmaz, H
dc.date.accessioned2019-10-27T11:52:27Z
dc.date.available2019-10-27T11:52:27Z
dc.date.issued1998
dc.departmentEge Üniversitesien_US
dc.description.abstractObjectives: Although the pathophysiology of syndrome X (angina pectoris, positive ECG test findings and normal coronary arteriogram) is unclear, it is generally accepted that intracellular metabolic changes resulting from abnormal constriction of prearteriolar vessels due to endothelium-dependent vasodilation abnormalities may play a role in the pathogenesis. We established the effect of long-term treatment with cilazapril, an angiotensin-converting enzyme inhibitor, which prevents the effect of angiotensin II in the tonic control of vascular resistance. Methods: 18 patients (15 women and 3 men, mean age 43.2 +/- 4.6 years) with syndrome X were included in this study. A randomized double-blind crossover placebo-controlled trial was done. After a 1-week washout period, patients received either cilazapril 2 x 2.5 mg or placebo for 3 weeks, followed by 3 weeks of the other therapy. At the end of two periods, an exercise ECG test (modified Bruce protocol) was employed. Results: The magnitude of ST segment depression was significantly decreased during treatment with cilazapril compared with placebo. On the other hand, total exercise time and time to 1 mm ST segment depression were significantly prolonged by cilazapril. However, rate pressure products were not significantly different at peak exercise at or at 1 mm of ST segment depression during both therapies. Conclusion: Cilazapril exerted a beneficial therapeutic effect in cases with syndrome X. The possible mechanism of this effect may be a modulation of coronary tone at the microcirculation level.en_US
dc.identifier.doi10.1159/000006768en_US
dc.identifier.endpage133en_US
dc.identifier.issn0008-6312
dc.identifier.issue2en_US
dc.identifier.pmid9524014en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage130en_US
dc.identifier.urihttps://doi.org/10.1159/000006768
dc.identifier.urihttps://hdl.handle.net/11454/34743
dc.identifier.volume89en_US
dc.identifier.wosWOS:000072100800008en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherKargeren_US
dc.relation.ispartofCardiologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectsyndrome Xen_US
dc.subjectcilazaprilen_US
dc.subjectACE inhibitorsen_US
dc.titleTherapeutic benefits of cilazapril in patients with syndrome Xen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu